Oncoinvent ASA Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist

This Oncoinvent ASA Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP establishes pipeline ownership and stage, reconstructs transaction precedents and surfaces financial signals; Current Awareness MCP adds recent events and outreach clues. Explore the MCP servers used in this report.

Decision date: 24 July 2026. Currency fields are presented in US$ millions where returned. This is a screening memorandum, not legal, medical, patent or investment advice.

Executive BD screen

Oncoinvent ASA returned 12 pipeline records in the organization search. The near-term screen centers on Radspherin, reported at Phase 2, with ownership attributed to Oncoinvent ASA (Old). The Oncoinvent ASA official organization website passed the external-link verification gate; ownership still requires confirmation against current corporate and asset records.

The practical partnering thesis is to qualify the current owner, validate the evidence package behind the next development milestone, and determine whether geography, indication, combination, manufacturing or option rights remain available. The shortlist below is prioritized by returned maturity rather than an unverified probability-of-success score.

Partnering shortlist

Owner caution: returned owner names include Oncoinvent ASA (Old); Oncoinvent ASA. Confirm legal entity, chain of title, encumbrances and sublicensing authority before relying on the owner field.

Evidence package to request

• Clinical: protocol, statistical analysis plan, patient-level disposition, efficacy tables, safety narratives, biomarker plan and regulator correspondence for Radspherin.
• Translational: target engagement, dose–exposure–response, model relevance, resistance hypotheses and differentiation versus current standard of care.
• CMC: process description, specifications, comparability history, stability, scale-up assumptions, critical suppliers and cost-of-goods model.
• Commercial: target product profile, addressable segments, competitive trials, pricing/access assumptions and regional launch requirements.
• Corporate: cap table, program budget, existing alliances, change-of-control terms and a complete schedule of third-party obligations.

IP and freedom-to-operate risk

Target annotation was not returned; prioritize identity, composition-of-matter, formulation, use-claim and assignment-chain review. The scan does not substitute for claim-chart analysis. Diligence should reconcile patent-family ownership, inventorship, priority support, prosecution status, expiry and patent-term adjustment, licenses, government funding, employee/consultant assignments, oppositions and litigation. Separate platform blocking risk from asset-specific composition, use, dosing, formulation and manufacturing risk.

Deal precedent and transaction framing

• BerGenBio and Oncoinvent announce that they have entered into a merger agreement to combine the two companies through a statutory merger, where BerGenBio will be the acquiring entity. (2025-06-30). Economics were not disclosed in the returned record.
• BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer (2024-08-20). Economics were not disclosed in the returned record.

Use returned transactions as negotiation anchors only after normalizing modality, stage at signing, territory, option structure, cost sharing and development obligations. Where no directly comparable precedent is returned, construct a broader target-, modality- and indication-level set before proposing economics.

Financial signals

• OncoTherapy Science, Inc. - Annual securities report-17th Period(2017.04.01-2018.03.31): OncoTherapy Science, Inc. - Annual securities report-17th Period(2017.04.01-2018.03.31) ③ 技术革新について なお、研究开発の状况の详细につきましては、「第２ 事业の状况 ５研究开発活动 （2）研究开発活动 ◇がんプレシジョン医疗関连事业◇」 をご覧ください。 ②キャッシュ・フローの状况 当连结会计年度における现金及び现金同等物（以下「资金」という。）は、6,740百万円（前连结会计年度末比 3,332百万円减少）となりました。 当连结会计年度のキャッシュ・フローの概况は以下の通りです。 （営业活动によるキャッシュ・フロー）…
• REVELATION BIOSCIENCES, INC. - 2022 Annual report: REVELATION BIOSCIENCES, INC. - 2022 Annual report Recent Developments Our use of cash is to fund operating expenses, which consist primarily of research and development expenditures related to our therapeutic product candidate, REVTx-300, REVTx-100 and REVTx-200. We plan to increase our research and development expenses substantially for the foreseeable…

Financial-report passages are outreach signals rather than a valuation model. Translate them into questions about runway, program prioritization, non-dilutive capital needs, development-cost sharing and willingness to trade territory for funding or capabilities.

Recent events and timing clues

• Current Awareness MCP did not return a company-specific recent event for this query. Confirm material events, trial changes, financing and partnering activity through current disclosures.

Reconfirm every time-sensitive event before contact. The strongest outreach window is normally just before a financing, data readout, regulator interaction, indication expansion or manufacturing commitment—when a partner can change the risk or capital profile.

Recommended outreach sequence

1. Confirm ownership: contact business development and legal with a one-page statement of interest naming Radspherin, territory and proposed collaboration type.
2. Request a staged data room: begin with non-confidential evidence, then gate patient-level, CMC and IP materials under NDA.
3. Offer a specific value exchange: link capital, development execution, regulatory access, manufacturing or commercialization reach to the owner’s next milestone.
4. Propose structure: compare regional license, option-to-license, co-development and asset acquisition pathways with explicit decision points.
5. Define stop/go criteria: ownership defects, unsupported differentiation, unmanageable safety/CMC risk or blocking IP should pause valuation work.

Decision gates for the partnering team

Advance the opportunity only when four gates can be answered with traceable evidence. First, the legal owner must control the asset and the rights under discussion. Second, the next development milestone must be supported by a coherent clinical, translational and CMC package. Third, the proposed partner must contribute a capability that changes probability, timing, cost or commercial reach rather than merely adding capital. Fourth, the transaction must remain attractive after probability adjustment, remaining development spend, competitive displacement and third-party obligations.

At the initial screen, classify each gate as supported, unresolved or adverse. Unresolved items become dated data-room requests with a named owner; adverse items require a mitigation plan and explicit valuation effect. This discipline keeps early enthusiasm from turning missing evidence into an implicit positive assumption and gives both parties a clear path from introductory outreach to diligence, governance design and executable economics.

BD conclusion

Oncoinvent ASA merits a targeted, evidence-gated outreach centered on Radspherin and its reported Phase 2 status. The initial objective is not to negotiate headline economics; it is to resolve current ownership, evidence readiness, strategic fit and rights availability. A successful first interaction should produce a clean owner map, milestone calendar, diligence index and agreed pathway to a term-sheet discussion.

Build your next partnering scan with PatSnap MCP. Connect pipeline, transaction, financial and current-awareness evidence through the PatSnap MCP server marketplace.